【编辑推荐】本研究首次揭示酮内酯类抗生素Cethromycin通过靶向疟原虫顶质体（apicoplast）实现单剂量根治伯氏疟原虫（P. berghei）肝期感染的机制，其肝脏药物浓度达血浆440倍，60 mg/kg剂量（等效人类300 mg）可实现100%治愈率，为休眠期间日疟（P. vivax）根治提供了无需G6PD检测的安全替代方案。

Cethromycin demonstrated a favorable safety profile in Trial CL-05. The incidence of adverse events was not statistically different between cethromycin and Biaxin.

Cethromycin was evaluated using a 300 mg once-daily dosing regimen compared to 250 mg twice-daily dosing for Biaxin, both over a seven-day course of therapy.

Co announces Cethromycin at 300 mg once daily for seven days was well tolerated by subjects with hepatic impairment and subjects with normal hepatic function.

Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure ...

Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial CHICAGO, June 21, 2007 -- Advanced Life Sciences Holdings, Inc. , today announced positive results from Trial CL ...

Advanced Life Sciences Holdings Inc. is proceeding with its new drug application (NDA) for cethromycin in community-acquired pneumonia (CAP) after results of the second of two pivotal clinical trials ...

Cethromycin cured pneumonia in 92.8% of patients in two clinical trials involving a total of 1,100 patients, versus a 94.9% cure rate for the commonly used drug Biaxin from Abbott Laboratories .

Cethromycin is important in the $5 billion global market for pneumonia antibiotics because bacteria that cause pneumonia increasingly are resistant to therapies now available, said John Flavin ...

Ketek and cethromycin are aimed at patients who get pneumonia outside of a hospital or extended-care facility. This community-acquired pneumonia, or CAP, is a common lung inflammation often caused ...

However, Cethromycin, which has been tested in more than 4,400 people, was developed primarily as a treatment for pneumonia. Results of Phase III human trials should be available next month.

Under the $2 million deal, Advanced Life Sciences will work to establish cethromycin as a broad-spectrum medical countermeasure bio-support defense therapy. Advertisement ...